Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 12/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13264442 | 0.91 | KCNH2 (0.45) | CNR2CNR1KCNH2MCHR1MAPT | |
| SCHEMBL5040949 | 0.88 | KCNH2 (0.49) | CNR2CNR1KCNH2MCHR1 | |
| SCHEMBL12002166 | 0.88 | CNR2 (0.47) | CNR2CNR1KCNH2MCHR1MAPT | |
| SCHEMBL12002326 | 0.88 | KCNH2 (0.58) | CNR2CNR1KCNH2MCHR1 | |
| SCHEMBL2798529 | 0.86 | KCNH2 (0.45) | CNR2CNR1KCNH2MCHR1 | |
| SCHEMBL12002139 | 0.85 | KCNH2 (0.59) | CNR2KCNH2MCHR1 | |
| SCHEMBL13264481 | 0.85 | KCNH2 (0.46) | CNR2KCNH2MCHR1MAPT | |
| SCHEMBL12002254 | 0.85 | KCNH2 (0.43) | KCNH2MCHR1 | |
| SCHEMBL2793456 | 0.85 | KCNH2 (0.59) | CNR2CNR1KCNH2MCHR1 | |
| SCHEMBL13264491 | 0.84 | KCNH2 (0.42) | KCNH2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | CNR2 807/4885CNR1 673/4885KCNH2 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.